Skip to main content
. 2014 Nov 4;112(1):162–166. doi: 10.1038/bjc.2014.566

Table 2. OR (95% CI) for ovarian cancer by tertiles and for doubling of IGF-I by tumour characteristics and menopausal statusa.

Tertilesb
    1 2 3 ORlog2 (95% CI) Ptrendc Phetd
Overall 565 sets ref. 0.93 (0.72–1.20) 0.92 (0.70–1.20) 0.88 (0.71–1.08) 0.21  
Histology
Serous 302 sets ref. 1.02 (0.72–1.46) 1.03 (0.71–1.48) 0.98 (0.74–1.30) 0.90  
Mucinous 41 sets ref. 1.07 (0.42–2.73) 0.60 (0.20–1.82) 0.59 (0.24–1.42) 0.24  
Endometrioid 66 sets ref. 1.01 (0.43–2.34) 0.93 (0.37–2.32) 0.73 (0.34–1.56) 0.42  
Clear cell 28 sets ref. 1.52 (0.43–5.36) 0.99 (0.29–3.40) 0.89 (0.37–2.13) 0.80  
NOS 99 sets ref. 0.63 (0.36–1.12) 0.67 (0.36–1.24) 0.75 (0.48–1.17) 0.21  
Other 29 sets ref. 0.89 (0.28–2.78) 1.71 (0.42–6.87) 1.07 (0.40–2.83) 0.89 0.12
Grade
Low grade 35 sets ref. 0.24 (0.06–1.08) 0.56 (0.15–2.00) 0.87 (0.34–2.24) 0.78  
High grade 306 sets ref. 0.95 (0.68–1.34) 1.01 (0.70–1.47) 0.96 (0.72–1.28) 0.79 0.89
Stage
Low stage 76 sets ref. 1.23 (0.57–2.67) 1.39 (0.65–3.01) 1.02 (0.56–1.85) 0.95  
High stage 419 sets ref. 0.98 (0.73–1.31) 0.87 (0.64–1.19) 0.86 (0.68–1.09) 0.21 0.52
Type I/II
Type I 67 sets ref. 0.69 (0.31–1.54) 0.72 (0.32–1.62) 0.84 (0.43–1.64) 0.61  
Type II 242 sets ref. 1.04 (0.70–1.54) 1.16 (0.76–1.78) 1.02 (0.73–1.42) 0.90 0.71
Menopausal status
Premenopausal 112 sets ref. 0.56 (0.27–1.16) 0.69 (0.34–1.40) 0.93 (0.55–1.58) 0.80  
Postmenopausal 452 sets ref. 1.01 (0.77–1.32) 0.93 (0.70–1.26) 0.87 (0.69–1.08) 0.21 0.69
Age at diagnosis
<55 years 105 sets ref. 0.46 (0.22–0.95) 0.66 (0.33–1.32) 0.91 (0.55–1.50) 0.70  
⩾55 years 459 sets ref. 1.04 (0.79–1.36) 0.95 (0.71–1.28) 0.87 (0.70–1.09) 0.23 0.83

Abbreviations: CI=confidence interval; IGF-I=insulin-like growth factor I; OR=odds ratio.

a

Matched for study centre, age at blood donation, menopausal status, time of day of blood collection, fasting status and phase of the menstrual cycle and additionally adjusted for ever full-term pregnancy (never/ever).

b

Phase-specific cut-offs; raw data IGF-I (nmol l−1) for phase 1: first tertile 16.30–23.61; second tertile 23.62–33.95; third tertile: >33.95. Phase 2: first tertile 8.05–10.95; second tertile 10.96–15.10; third tertile >15.10.

c

Linear trends for OR estimated on log2 continuous scale.

d

Statistical tests for heterogeneity were based on likelihood ratio test, comparing the model fit for logistic regression models with and without corresponding interaction term.